Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

852
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
852
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.0K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Study of Sporadic and Immune Checkpoint Inhibitor-Related Forms of Myasthenia Gravis-Myositis Overlap Syndrome.

Neurology·2026
Same author

The novel (TCTG)<sub>n</sub> motif in CNBP expanded alleles: composition, dynamics and genotype-phenotype correlation in Myotonic dystrophy type 2 (DM2).

Human genomics·2026
Same author

Diagnostic Performance of Three Serological Assays in Myasthenia Gravis: A Prospective Multicentre Study.

Scandinavian journal of immunology·2025
Same author

Prevalence and Clinical Correlates of Sleep Disorders in RFC1-Spectrum Disorders: A Cross-Sectional Study.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

Mutated sigma-1R disrupts cell homeostasis in dHMN patient cells.

Cellular and molecular life sciences : CMLS·2025
Same author

Correction to: Spinocerebellar ataxia 27B: a frequent and slowly progressive autosomal-dominant cerebellar ataxia-experience from an Italian cohort.

Journal of neurology·2024

Related Experiment Video

Updated: Dec 22, 2025

An Automated T-maze Based Apparatus and Protocol for Analyzing Delay- and Effort-based Decision Making in Free Moving Rodents
07:42

An Automated T-maze Based Apparatus and Protocol for Analyzing Delay- and Effort-based Decision Making in Free Moving Rodents

Published on: August 2, 2018

14.2K

Ventral tegmental area dysfunction affects decision-making in patients with myotonic dystrophy type-1.

Laura Serra1, Marta Scocchia1, Giovanni Meola2

  • 1Neuroimaging Laboratory, IRCCS Fondazione Santa Lucia, Rome, Italy.

Cortex; a Journal Devoted to the Study of the Nervous System and Behavior
|May 4, 2020
PubMed
Summary

Myotonic Dystrophy type-1 (DM1) patients show impaired decision-making due to altered ventral tegmental area (VTA) brain connectivity. These findings suggest dopaminergic function is a key target for DM1 interventions.

Keywords:
CognitionConnectivityDM1DopaminefMRI

More Related Videos

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.8K
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.8K

Related Experiment Videos

Last Updated: Dec 22, 2025

An Automated T-maze Based Apparatus and Protocol for Analyzing Delay- and Effort-based Decision Making in Free Moving Rodents
07:42

An Automated T-maze Based Apparatus and Protocol for Analyzing Delay- and Effort-based Decision Making in Free Moving Rodents

Published on: August 2, 2018

14.2K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.8K
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.8K

Area of Science:

  • Neuroscience
  • Genetics
  • Cognitive Science

Background:

  • Myotonic Dystrophy type-1 (DM1) causes multisystem issues, including cognitive deficits impacting social and occupational life.
  • Decision-making, crucial for functioning, relies on dopaminergic pathways.

Purpose of the Study:

  • To investigate if altered ventral tegmental area (VTA) connectivity contributes to higher-level cognitive dysfunctions in DM1 patients.
  • To explore the relationship between VTA connectivity and decision-making performance.

Main Methods:

  • Case-control study with 31 DM1 patients and 26 healthy controls.
  • Utilized the IOWA Gambling Task (IGT) and resting-state functional MRI (RS-fMRI).
  • Assessed VTA functional connectivity and its association with IGT performance.

Main Results:

  • DM1 patients performed significantly worse on the IGT compared to controls.
  • Increased VTA functional connectivity was observed with the left supramarginal and superior temporal gyri in DM1 patients.
  • IGT performance correlated with VTA connectivity in the supplementary motor area and precentral gyrus.

Conclusions:

  • DM1 is associated with significant decision-making deficits.
  • Altered VTA connectivity may underlie these deficits, impacting reward processing and social cognition.
  • Dopaminergic function represents a potential therapeutic target for DM1.